Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149920332> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W3149920332 abstract "Ulcerative colitis and Crohn’s disease are the major phenotypes of the idiopathic inflammatory bowel disease(IBD),which afflicts millions of individuals throughout the world with debilitating symptoms,impairing function and quality of life.Current medications are aimed at reducing the symptoms or suppressing exacerbations.However,patients require life-long medications,and this can lead to drug dependency,loss of response together with adverse side effects.Indeed,drug side effects become additional morbidity factor in many patients on long-term medications.Nonetheless,the efficacy of anti-tumour necrosis factors(TNF)-αbiologics has validated the role of inflammatory cytokines notably TNF-αin the exacerbation of IBD.However,inflammatory cytokines are released by patients’own cellular elements including myeloid lineage leucocytes,which in patients with IBD are elevated with activation behaviour and prolonged survival.Accordingly,these leucocytes appear logical targets of therapy and can be depleted by adsorptive granulocyte/monocyte apheresis(GMA)with an Adacolumn.Based on this background,recently GMA has been applied to treat patients with IBD in Japan and in the European Union countries.Efficacy rates have been impressive as well as disappointing.In fact the clinical response to GMA seems to define the patients’disease course,response to medications,duration of active disease,and severity at entry.The best responders have been first episode cases(up to 100%)followed by steroid nave and patients with a short duration of active disease prior to GMA.Patients with deep ulcers together with extensive loss of the mucosal tissue and cases with a long duration of IBD refractory to existing medications are not likely to benefit from GMA.It is clinically interesting that patients who respond to GMA have a good long-term disease course by avoiding drugs including corticosteroids in the early stage of their IBD.Additionally,GMA is very much favoured by patients for its good safety profile.GMA in 21st century reminds us of phlebotomy as a major medical practice at the time of Hippocrates.However,in patients with IBD,there is a scope for removing from the body the sources of proinflammatory cytokines and achieve disease remission.The bottom line is that by introducing GMA at an early stage following the onset of IBD or before patients develop extensive mucosal damage and become refractory to medications,many patients should respond to GMA and avoid pharmacologics.This should fulfill the desire to treat without drugs." @default.
- W3149920332 created "2021-04-13" @default.
- W3149920332 creator A5034040888 @default.
- W3149920332 date "2014-01-01" @default.
- W3149920332 modified "2023-09-25" @default.
- W3149920332 title "Treating inflammatory bowel disease by adsorptive leucocytapheresis:A desire to treat without drugs" @default.
- W3149920332 hasPublicationYear "2014" @default.
- W3149920332 type Work @default.
- W3149920332 sameAs 3149920332 @default.
- W3149920332 citedByCount "0" @default.
- W3149920332 crossrefType "journal-article" @default.
- W3149920332 hasAuthorship W3149920332A5034040888 @default.
- W3149920332 hasConcept C126322002 @default.
- W3149920332 hasConcept C197934379 @default.
- W3149920332 hasConcept C203014093 @default.
- W3149920332 hasConcept C2777014857 @default.
- W3149920332 hasConcept C2777138892 @default.
- W3149920332 hasConcept C2778260677 @default.
- W3149920332 hasConcept C2779134260 @default.
- W3149920332 hasConcept C2779280984 @default.
- W3149920332 hasConcept C2780035454 @default.
- W3149920332 hasConcept C2780479503 @default.
- W3149920332 hasConcept C71924100 @default.
- W3149920332 hasConcept C98274493 @default.
- W3149920332 hasConceptScore W3149920332C126322002 @default.
- W3149920332 hasConceptScore W3149920332C197934379 @default.
- W3149920332 hasConceptScore W3149920332C203014093 @default.
- W3149920332 hasConceptScore W3149920332C2777014857 @default.
- W3149920332 hasConceptScore W3149920332C2777138892 @default.
- W3149920332 hasConceptScore W3149920332C2778260677 @default.
- W3149920332 hasConceptScore W3149920332C2779134260 @default.
- W3149920332 hasConceptScore W3149920332C2779280984 @default.
- W3149920332 hasConceptScore W3149920332C2780035454 @default.
- W3149920332 hasConceptScore W3149920332C2780479503 @default.
- W3149920332 hasConceptScore W3149920332C71924100 @default.
- W3149920332 hasConceptScore W3149920332C98274493 @default.
- W3149920332 hasLocation W31499203321 @default.
- W3149920332 hasOpenAccess W3149920332 @default.
- W3149920332 hasPrimaryLocation W31499203321 @default.
- W3149920332 hasRelatedWork W1947587534 @default.
- W3149920332 hasRelatedWork W1966167275 @default.
- W3149920332 hasRelatedWork W1968087181 @default.
- W3149920332 hasRelatedWork W1978593886 @default.
- W3149920332 hasRelatedWork W1980483265 @default.
- W3149920332 hasRelatedWork W2022736561 @default.
- W3149920332 hasRelatedWork W2093290828 @default.
- W3149920332 hasRelatedWork W2093555382 @default.
- W3149920332 hasRelatedWork W2119500208 @default.
- W3149920332 hasRelatedWork W2171792149 @default.
- W3149920332 hasRelatedWork W2292948016 @default.
- W3149920332 hasRelatedWork W2301603300 @default.
- W3149920332 hasRelatedWork W2513937749 @default.
- W3149920332 hasRelatedWork W2767476453 @default.
- W3149920332 hasRelatedWork W2791720823 @default.
- W3149920332 hasRelatedWork W3145170615 @default.
- W3149920332 hasRelatedWork W3148416520 @default.
- W3149920332 hasRelatedWork W3196467244 @default.
- W3149920332 hasRelatedWork W2127544600 @default.
- W3149920332 hasRelatedWork W2151737448 @default.
- W3149920332 isParatext "false" @default.
- W3149920332 isRetracted "false" @default.
- W3149920332 magId "3149920332" @default.
- W3149920332 workType "article" @default.